Corcept Therapeutics Chief Business Officer Gary Charles Robb Reports Bona Fide Gift of 17,100 Shares

Executive Summary

On September 28, 2026, Corcept Therapeutics Inc ($CORT) filed a Form 4 disclosing that Chief Business Officer Gary Charles Robb disposed of 17,100 shares of common stock on September 24, 2026, via a bona fide gift (Transaction Code G) at $0.00 per share.

Transaction Details

• Direct Disposition: Mr. Robb gifted 17,100 directly held shares, reducing his direct ownership to 14,056 shares (which includes unvested restricted stock awards).
• Indirect Acquisitions: Concurrently, two gifts of 5,000 shares each were recorded as indirect acquisitions by custodial accounts for his children under the Uniform Transfers to Minors Act, bringing each custodial holding to 20,571 shares.
• Additional Holdings: Mr. Robb also maintains indirect beneficial ownership of 39,716 shares held through the Gary Charles Robb TTE Robb Revocable Trust.

Market & Trading Significance

This transaction represents routine estate planning and family wealth transfer rather than an open-market sale or purchase. Because no cash was exchanged and shares were transferred to family custodial accounts, this filing carries Low trading significance and provides no directional signal regarding company fundamentals.